title: Erectile dysfunction: intracavernous treatment.
abstract: The intracavernous use of papaverine, phentolamine and prostaglandin E1 (PGE1) is reviewed. The value of treatment combinations is also considered. In particular, the beneficial and harmful effects of long-term intracavernous treatment are considered. For example, the use of PGE1 may be associated with a long-term improvement of the penile microcirculation. In order to maximise the benefit from intracavernous therapy there is a need for specialised evaluations, a stepwise management approach and the consideration of patient preference.
authors.affiliation: Centro di Ricerche in Andrologia, Pescara, Italy. andrealedda@tin.it
authors.forename: A
authors.initials: A
authors.lastname: Ledda
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000494:pharmacology; D000527:Alprostadil / Q000008:administration & dosage* / Q000494:pharmacology; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008297:Male; D010208:Papaverine / Q000008:administration & dosage* / Q000494:pharmacology; D010646:Phentolamine / Q000008:administration & dosage* / Q000494:pharmacology; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D000317:Adrenergic alpha-Antagonists; D014665:Vasodilator Agents; D010208:Papaverine; D000527:Alprostadil; D010646:Phentolamine